PIA
AXDX

Piedmont Investment Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Piedmont Investment Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-45
Closed -$10K – 1143
2018
Q2 		$10K Buy
+45
New +$10.1K ﹤0.01% 1822

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Piedmont Investment Advisors's AXDX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Accelerate Diagnostics (AXDX) in Q3 2018, closing a stake of 45 shares — an estimated $10K sold.

Piedmont Investment Advisors first reported a position in AXDX in Q2 2018 and held it in 1 quarter. The position peaked at $10K in Q2 2018. 119 funds tracked by Wall St. Rank hold AXDX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Accelerate Diagnostics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 45 Accelerate Diagnostics shares in Q3 2018, an estimated $10K.
  • Piedmont Investment Advisors first reported a position in Accelerate Diagnostics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Accelerate Diagnostics position peaked at $10K in Q2 2018.
  • 119 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.